Key Points {#FPar1}
==========

Cardiotoxicity is an important therapeutic limitation of the human epidermal growth factor receptor 2 (HER2) blocker trastuzumab.ABP 980 is a biosimilar to trastuzumab (Herceptin^®^) reference product (RP).The cardiac safety of ABP 980 was compared with its RP in the phase III LILAC study, and the incidence of cardiac adverse events was found to be low and comparable in the treatment groups, with no new cardiac safety signals observed with ABP 980.

Introduction {#Sec1}
============

ABP 980 is a biosimilar to Herceptin^®^ (trastuzumab; Roche Registration GmbH, Germany; Genentech, San Francisco, USA). Herceptin^®^ is approved for use in the United States (US), the European Union (EU), Japan, and much of the rest of the world for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer, and is the standard of care for subjects with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer \[[@CR1], [@CR2]\]. In the recent phase III LILAC trial (ClinicalTrials.gov identifier NCT01901146), ABP 980 was shown to be similar to the trastuzumab reference product (RP) with respect to efficacy, safety, and immunogenicity in women with HER2-positive early breast cancer, with no clinically meaningful difference between the two products \[[@CR3]\]. The LILAC study found that the frequency, type, and severity of adverse events (AEs), including cardiac events, were comparable between treatment arms and were consistent with the known safety profile of trastuzumab \[[@CR1], [@CR3], [@CR4]\]. Based in part on these data, and the totality of evidence generated during development, ABP 980 (KANJINTI™ \[trastuzumab\], Amgen Europe B.V., The Netherlands) was approved by the European Medicines Agency in May 2018 for the same indications as Herceptin^®^, including the treatment of HER2-positive metastatic breast cancer, HER2-positive early breast cancer, and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction \[[@CR5]\]. Since then, the US FDA has also approved ABP 980 (KANJINTI™ \[trastuzumab-anns\], Amgen Inc., Thousand Oaks, CA, USA) for all approved indications of the RP \[[@CR6]\].

While trastuzumab is generally well-tolerated, cardiac toxicity remains a rare but serious concern and may limit the therapeutic potential of trastuzumab in a subset of patients \[[@CR7]\]. HER2 is known to play an important role in cardiac development and may also play a physiologic role in normal cardiac function \[[@CR7], [@CR8]\]. The mechanism of cardiac toxicity is not entirely understood but studies suggest that it may involve HER2 blockade. Trastuzumab-induced cardiotoxicity may result from decreased HER2 signaling required for cardiac contractility, interference with cardiomyocyte survival signals, and compromised myocyte stress response \[[@CR7], [@CR8]\].

Left ventricular systolic dysfunction is the most concerning cardiac toxicity associated with trastuzumab, particularly when it is administered in combination with an anthracycline \[[@CR7]\]. Adjuvant clinical trials of trastuzumab have reported severe heart failure in 1.44--4% of patients; the overall risk ratio (RR) of high-grade heart failure was reported to be 3.04-fold higher with trastuzumab than without \[[@CR9], [@CR10]\]. Moreover, up to 19% of patients were reported to have developed a significant decline in left ventricular ejection fraction (LVEF) \[[@CR9], [@CR11]\]. However, the TRYPHAENA study, which assessed the cardiac safety of trastuzumab and pertuzumab with chemotherapy during the neoadjuvant treatment of 225 women with HER2-positive early breast cancer, showed a low incidence of symptomatic left ventricular systolic dysfunction \[[@CR12], [@CR13]\].

In this study, we examine in greater detail the cardiac safety of ABP 980 compared with trastuzumab RP in the LILAC study.

Materials and Methods {#Sec2}
=====================

The study design is shown in Fig. [1](#Fig1){ref-type="fig"} and has been described in detail previously \[[@CR3]\]. Briefly, this randomized, multicenter, double-blind, active-controlled equivalence trial compared ABP 980 with trastuzumab RP in adult women with HER2-positive early breast cancer. Patients included women ≥ 18 years of age with histologically confirmed invasive breast cancer and with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, were planned to receive neoadjuvant therapy and subsequent surgical resection of breast tumor and sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND), had HER2-positive disease (confirmed by a central laboratory before patients were randomized) defined as 3 + overexpression by immunohistochemistry or HER2 amplification by fluorescence in situ hybridization and with known estrogen and progesterone hormone receptor status at study entry, measurable disease in the breast after diagnostic biopsy, defined as the longest diameter ≥ 2.0 cm, and LVEF ≥ 55% by two-dimensional (2D) echocardiogram.Fig. 1LILAC: trial design(modified from von Minckwitz et al. \[[@CR3]\])

Exclusion criteria included the presence of bilateral breast cancer or known distant metastases; prior treatment including chemotherapy, biologic therapy, radiation, or surgery for primary breast cancer; concomitant active malignancy; and had concomitant active malignancy or a history of malignancy in the past 5 years, except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.

After a 28-day screening period, patients entered a neoadjuvant treatment period to receive run-in chemotherapy consisting of epirubicin and cyclophosphamide (EC) every 3 weeks (Q3W) for four cycles, followed by surgery within 3--7 weeks of the last dose of investigational product (IP) in the neoadjuvant phase. Once run-in chemotherapy was completed, patients with adequate cardiac function were randomized 1:1 to treatment with ABP 980 (Amgen Inc., Thousand Oaks, CA, USA) or trastuzumab RP (Herceptin^®^; Genentech, San Francisco, CA, USA) plus paclitaxel Q3W for four cycles; paclitaxel once weekly (QW) was also allowed if consistent with local standard of care. Randomization was stratified according to tumor or T stage (\< T4, T4), node status (yes, no), hormone receptor status (estrogen receptor \[ER\]-negative and/or progesterone receptor \[PR\]-positive vs. ER-negative and PR-negative), planned paclitaxel dosing schedule (QW, Q3W), and geographic region (Eastern Europe, Western Europe, or other). IP was administered at an initial dose of 8 mg/kg over 90 min, followed by 6 mg/kg intravenous infusions for three cycles.

Surgery (lumpectomy or mastectomy with SLND or ALND) was completed 3--7 weeks after the last dose of IP in the neoadjuvant phase. An adjuvant phase followed surgery, during which patients received ABP 980 or a trastuzumab RP 6 mg/kg intravenous infusion Q3W for up to 1 year starting from the first day of IP administration in the neoadjuvant phase. In the adjuvant phase, patients who initially received ABP 980 during the neoadjuvant phase continued receiving ABP 980 Q3W; patients who initially received trastuzumab RP during the neoadjuvant phase were randomized to either continue receiving trastuzumab Q3W or switched to ABP 980 Q3W (trastuzumab RP/ABP 980 group). Allocation to the neoadjuvant and adjuvant (including the single switch) treatment arm occurred at randomization and was maintained in a blinded manner.

AEs and disease progression or recurrence were assessed at each visit during the neoadjuvant and adjuvant periods.

During the adjuvant phase, the following assessments/evaluations were made: AEs, serious AEs (SAEs), concomitant medications, disease progression or recurrence, and hematology sampling (all cycles); physical examination, vital signs and weight, serum chemistry, anti-drug antibody (ADA) sampling (cycles 5, 9, and 13), and pharmacokinetic sampling. AEs were monitored by investigators or reported by the patients after randomization through 30 days after the last dose of IP.

Cardiac Monitoring {#Sec3}
------------------

For cardiac safety monitoring, computerized 12-lead electrocardiogram (ECG) recordings were obtained for heart rate, P, PR, QRS, QT, and QTc intervals. A copy of all ECGs were retained on site and could be collected for central review if required (i.e. in case emerging ECG data necessitated expert evaluation). ECGs could be repeated for quality reasons and additional ECGs could be collected by investigators for safety reasons. Any new clinically relevant abnormal findings were reported as AEs. Patients with clinically relevant cardiovascular adverse effects or AEs (or clinically relevant ECG changes) were withdrawn from study treatment per protocol.

To assess LVEF, a 2D echocardiogram was performed per local standard-of-care guidelines. During the neoadjuvant phase, the 2D echocardiogram was performed at screening, baseline (cycle 1) and at cycle 4 (last visit of the neoadjuvant phase) (Fig. [1](#Fig1){ref-type="fig"}). At all indicated visits, the 2D echocardiogram was required to be performed and results obtained prior to IP administration. During the adjuvant phase, 2D echocardiograms were performed at cycles 9 and 13. A 2D echocardiogram was also performed during the end-of-treatment (EOT, cycle 17) and end-of-study (EOS) visits; EOS visits were scheduled 30 days after the last IP, or 1 year from the first IP for subjects who withdrew early but remained on scheduled assessments. Investigators were strongly urged to schedule the LVEF assessment at the same cardiac imaging facility that performed the patient's baseline LVEF assessment. If IP was discontinued for any reason, protocol-mandated LVEF assessments were obtained.

During IP treatment, if LVEF decreased by ≥ 10% points from the baseline (cycle 1) post-anthracycline/pre-randomization echocardiogram and to \< 50%, treatment was suspended and a repeat LVEF assessment was performed within approximately 3 weeks. If LVEF was not improved or if it declined further, IP was to be discontinued. If symptomatic cardiac failure developed during the IP treatment, it was treated according to local standard of care. The IP was required to be discontinued in subjects who developed clinically significant heart failure. Based on the known safety profile of trastuzumab, treatment-emergent cardiac failure was a prespecified event of interest (EOI) that was monitored closely during the study.

Results {#Sec4}
=======

Key demographics and baseline characteristics are summarized in Table [1](#Tab1){ref-type="table"}. For a complete list of demographic and baseline characteristics see von Minckwitz et al. \[[@CR3]\]. In general, the treatment groups were well balanced. At baseline, by neoadjuvant treatment, the mean LVEF was 64.67% (standard deviation \[SD\] 5.143) and 64.60% (SD 4.837) in the ABP 980 and trastuzumab arms, respectively. Cardiac findings at screening by neoadjuvant and neoadjuvant/adjuvant treatment for resolved and unresolved findings are summarized in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, respectively.Table 1Key demographic and study baseline characteristicsABP 980/ABP 980 (*N* = 364)Trastuzumab RP/trastuzumab RP (*N* = 190)Trastuzumab RP/ABP 980 (*N* = 171)Age, years \[mean (SD)\]52.8 (10.72)52.6 (10.90)52.7 (11.74)ECOG performance status Grade 0298 (81.9)163 (85.8)149 (87.1) Grade 166 (18.1)27 (14.2)22 (12.9)Tumor stage \< T4282 (77.5)147 (77.4)134 (78.4) T482 (22.5)43 (22.6)37 (21.6)Histologic grading Grade 18 (2.2)1 (0.5)0 Grade 2174 (47.8)93 (48.9)80 (46.8) Grade 3120 (33.0)67 (35.3)65 (38.0) Unknown62 (17.0)29 (15.3)26 (15.2)LVEF, % \[mean (SD)\]64.7 (5.14)64.6 (5.03)64.6 (4.63)Data are expressed as *n* (%) unless otherwise stated*ECOG* Eastern Cooperative Oncology Group, *LVEF* left ventricular ejection fraction, *RP* reference product, *SD* standard deviationTable 2General medical history by neoadjuvant/adjuvant treatment: resolved findingsABP 980/ABP 980 (*N* = 364)Trastuzumab RP/trastuzumab RP (*N* = 190)Trastuzumab RP/ABP 980 (*N* = 171)Total cardiac disorders6 (1.6)2 (1.1)1 (0.6)Atrial fibrillation2 (0.5)00Myocardial infarction2 (0.5)00Tachycardia1 (0.3)1 (0.5)0Acute myocardial infarction01 (0.5)0Left ventricular dysfunction1 (0.3)00Sinus tachycardia001 (0.6)Data are expressed as *n* (%)*RP* reference productTable 3General medical history: unresolved findings in two or more patients in any treatment groupABP 980/ABP 980 (*N* = 364)Trastuzumab RP/trastuzumab RP (*N* = 190)Trastuzumab RP/ABP 980 (*N* = 171)Total cardiac disorders64 (17.6)29 (15.3)26 (15.2)Myocardial ischemia12 (3.3)9 (4.7)6 (3.5)Mitral valve incompetence10 (2.7)8 (4.2)2 (1.2)Diastolic dysfunction9 (2.5)2 (1.1)6 (3.5)Left ventricular hypertrophy7 (1.9)5 (2.6)4 (2.3)Left ventricular dysfunction3 (0.8)3 (1.6)4 (2.3)Tricuspid valve incompetence5 (1.4)3 (1.6)2 (1.2)Aortic valve sclerosis4 (1.1)1 (0.5)2 (1.2)Arteriosclerosis coronary artery4 (1.1)2 (1.1)1 (0.6)Bundle branch block right3 (0.8)2 (1.1)1 (0.6)Hypertensive heart disease5 (1.4)01 (0.6)Cardiomyopathy1 (0.3)1 (0.5)2 (1.2)Coronary artery disease4 (1.1)00Left atrial dilatation1 (0.3)2 (1.1)1 (0.6)Mitral valve prolapse2 (0.5)2 (1.1)0Tachycardia2 (0.5)02 (1.2)Atrial fibrillation2 (0.5)1 (0.5)0Bundle branch block left3 (0.8)00Defect conduction intraventricular2 (0.5)01 (0.6)Arrhythmia2 (0.5)00Cardiac failure2 (0.5)00Sinus bradycardia2 (0.5)00Sinus tachycardia2 (0.5)00Data are expressed as *n* (%)*RP* reference product

Left Ventricular Ejection Fraction Decline {#Sec5}
------------------------------------------

On average, LVEF did not change over the course of the study and was comparable across the three treatment groups (Fig. [2](#Fig2){ref-type="fig"}). The number of patients experiencing LVEF decline by ≥10% and to \< 50% was low and comparable across treatment groups (Table [4](#Tab4){ref-type="table"}). Across the entire study, a total of 22 patients (3.1%) experienced LVEF decline by ≥10% and to \< 50%; the differences between treatment arms (ABP 980/ABP 980: 10 \[2.8%\]; trastuzumab RP/trastuzumab RP: 6 \[3.3%\]; trastuzumab RP/ABP 980: 6 \[3.5%\]) were not clinically meaningful. There were no meaningful differences between treatment arms in LVEF changes from baseline based on the lowest value reported for LVEF by neoadjuvant and adjuvant treatment. Overall, during the neoadjuvant phase, the incidence of LVEF decline was reported in 1 (0.3%) patient in the ABP 980 arm and 3 (0.9%) patients in the trastuzumab RP arm. The incidence of LVEF decline was higher in the adjuvant phase, but was similar between the treatment arms (ABP 980/ABP 980: 10 \[2.9%\]; trastuzumab RP/trastuzumab RP: 3 \[1.8%\]; trastuzumab RP/ABP 980: 6 \[3.6%\]).Fig. 2LVEF: summary by cycle. Baseline is defined as the last non-missing assessment taken prior to the first dose of study IP. Cycle 4 = visit 9; cycle 9 = visit 14; cycle 13 = visit 18. EOS visits were scheduled 30 days after the last IP, or 1 year from the first IP for subjects who withdrew early but remained on scheduled assessments. Results from unscheduled visits are included in these summaries. *LVEF* left ventricular ejection fraction, *IP* investigational product, *EOS* end of studyTable 4Patients experiencing LVEF decline by ≥ 10% and to \< 50% during the entire studyABP 980/ABP 980 (*N* = 364)Trastuzumab RP/trastuzumab RP (*N* = 190)Trastuzumab RP/ABP 980 (*N* = 171)Anytime during the study^a^10/359 (2.8)6/184 (3.3)6/171 (3.5)Cycle 41/345 (0.3)2/177 (1.1)0/167 (0.0)Cycle 90/334 (0.0)0/166 (0.0)0/160 (0.0)Cycle 132/316 (0.6)0/160 (0.0)1/160 (0.6)End of the study^b^9/336 (2.7)3/168 (1.8)5/160 (3.1)Data are expressed as *n/N1* (%). Cycle 4 = visit 9; cycle 9 = visit 14; cycle 13 = visit 18*IP* investigational product, *LVEF* left ventricular ejection fraction, *n* number of patients experiencing LVEF decline by ≥ 10% and to \< 50%, *N1* number of patients with data available at a given assessment, *RP* reference product^a^Results from unscheduled visits were included in the overall summary^b^End-of-study visits were scheduled 30 days after the last IP, or 1 year from the first IP for patients who withdraw early but remained on scheduled assessments

Assessment of onset time of LVEF decline (by ≥ 10% and to \< 50%) during the approximately 1 year of trastuzumab or ABP 980 treatment duration showed no definite patterns. Of the 22 events, 6 occurred before cycle 9, 6 between cycles 9 and 13, and 10 by EOT (cycle 13) or EOS (Table [5](#Tab5){ref-type="table"}).Table 5Characteristics of LVEF decline reported in the LILAC studyTreatment sequenceSubjectOnset by treatment cycleLVEF valueChange from baselineCV medical historyCardiac failure/ventricular hypokinesia AEDiscontinued due to AEABP 980/ABP 9801Baseline55− 18HypertensionHypercholesterolemiaNoNoCycle 13372Baseline64.4− 14.6HypertensionVentricular dysfunctionNoNoEOS49.83Baseline60− 15ArrhythmiaNoNoCycle 10^a^454Baseline69− 21Atrial fibrillationVaricose vein diseaseGrade 2 cardiac failureGrade 1 hypokinesiaNoEOS485Baseline61− 15Arterial hypertensionVaricose vein diseaseNoNoCycle 8^a^466Baseline64.9− 17.9Arterial hypertensionNoNoEOS477Baseline60− 14NoneNoNoCycle 8^a^468Baseline62− 15Mild diastolic dysfunctionDyslipidemiaNoNoCycle 4479Baseline62− 16HypertensionVenous insufficiencyHypercholesterolemiaNoNoCycle 134610Baseline60− 12HypertensionNoNoCycle 12^a^48Trastuzumab RP/ABP 98011Baseline55− 28NoneGrade 3 cardiac failureGrade 3 ventricular hypokinesiaYesEOS2712Baseline60− 14.6Arterial hypertensionNoNoEOS45.413Baseline59− 16HypertensionDiabetesGrade 3 ventricular hypokinesiaYesCycle 8^a^4314Baseline71.6− 23.6NoneNoNoCycle 134815Baseline65− 19Arterial hypertensionDiabetesNoNoEOT4616Baseline58− 18HypertensionNoNoEOS40Trastuzumab RP/trastuzumab RP17Baseline61− 13NoneNoNoEOS4818Baseline57− 14NoneNoNoCycle 44319Baseline63− 15DiabetesGrade 1 ventricular hypokinesiaNoCycle 44820Baseline63.2− 20.9HypertensionDiabetesObesityNoNoEOS42.321Baseline58− 23NoneGrade 2 ventricular hypokinesiaYesEOS3522Baseline55− 16.3HypertensionGrade 2 cardiac failureNoCycle 12^a^38.7*LVEF* left ventricular ejection fraction, *CV* cardiovascular, *AE* adverse event, *EOS* end of study, *EOT* end of treatment^a^Unscheduled visits

The majority of patients with LVEF decline had a prior history of cardiovascular and metabolic disorders, including hypertension, arrhythmia, atrial fibrillation, arterial hypertension, venous insufficiency, hypercholesterolemia, and diabetes (Table [5](#Tab5){ref-type="table"}). At screening, one patient had a slight delay of ventricular relaxation, and another had mild diastolic dysfunction; however, their LVEF values were normal at study initiation (Table [5](#Tab5){ref-type="table"}).

The majority of the LVEF declines were asymptomatic. There were three cardiac failure events (a prespecified EOI; discussed further in the following section), and three cases of ventricular hypokinesia that were coincident with LVEF decline by ≥ 10% points and to \< 50% compared with baseline (Table [5](#Tab5){ref-type="table"}).

Cardiac Failure {#Sec6}
---------------

The incidence of cardiac disorder AEs is shown in Table [6](#Tab6){ref-type="table"}. The incidence of any cardiac disorder was low across treatment groups (ABP 980/ABP 980: 35 \[9.6%\]; trastuzumab RP/trastuzumab RP: 14 \[7.4%\]; trastuzumab RP/ABP 980: 20 \[11.7%\]).Table 6Cardiac disorders (cardiotoxicity) from the entire studySystem organ class\
Preferred termABP 980/ABP 980 (*N* = 364)Trastuzumab RP/trastuzumab RP (*N* = 190)Trastuzumab RP/ABP 980 (*N* = 171)Any cardiac disorder AE35 (9.6)14 (7.4)20 (11.7)Cardiac failure5 (1.4)1 (0.5)1 (0.6)Cardiac failure chronic3 (0.8)00Cardiac failure congestive001 (0.6)Left ventricular dysfunction3 (0.8)1 (0.5)0Cardiotoxicity2 (0.5)1 (0.5)0Congestive cardiomyopathy1 (0.3)01 (0.6)Ventricular hypokinesia1 (0.3)3 (1.6)1 (0.6)Cardiomyopathy01 (0.5)1 (0.6)Tachycardia4 (1.1)2 (1.1)3 (1.8)Tachyarrhythmia1 (0.3)00Tachycardia paroxysmal001 (0.6)Cardiac failure EOIs by grade Grade 16 (1.6)0 (0.0)1 (0.6) Grade 22 (0.5)0 (0.0)0 (0.0) Grade 30 (0.0)1 (0.5)1 (0.6) Grade 4/50 (0.0)0 (0.0)0 (0.0)Data are expressed as *n* (%). AEs were coded using MedDRA version 19.0. Only treatment-emergent AEs were summarized. For each preferred term, patients were included only once, even if they experienced multiple events in that preferred term*AE* adverse event, *EOI*s events of interest, *MedDRA* Medical Dictionary for Regulatory Activities

Overall, the incidence of cardiac failure was comparable in the ABP 980/ABP 980 (8 \[2.2%\]), trastuzumab RP/trastuzumab RP (1 \[0.5%\]), and trastuzumab RP/ABP 980 (2 \[1.2%\]) groups. Most cardiac failure EOIs reported over the entire study were grade 1 (*n* = 7) or grade 2 (*n* = 3); none were grades 4 or 5. None of the cardiac failure EOIs were SAEs. All 11 subjects with cardiac failure EOIs were 50 years of age or older. Of the eight subjects with cardiac failure EOIs in the ABP 980/ABP 980 treatment arm, four had a relevant ongoing medical history of cardiac disease that may have contributed to cardiac failure EOIs. All 11 subjects who experienced cardiac failure EOIs underwent surgery and entered the adjuvant phase; one subject did not complete the planned IP dose and discontinued due to this AE; all others completed all planned doses of IP. In one subject (trastuzumab RP/ABP 980), the LVEF decline and cardiac failure AE had the same onset date, and the AE was considered possibly related. In two subjects, the cardiac failure AE was considered unlikely related: one subject (trastuzumab RP/trastuzumab RP) had cardiac failure 6 months after the LVEF decline, and one subject (ABP 980/ABP 980) had cardiac failure 3 months before LVEF decline. Of the 11 subjects, one subject in the ABP 980/ABP 980 arm had improved LVEF function at a subsequent visit (overall assessment of 'normal' following the report of grade 2 chronic cardiac failure; however, the subject experienced LVEF decline to \< 50% at the EOS visit).

During the neoadjuvant phase, seven patients experienced any cardiac failure AE (ABP 980: 6 \[1.6%\]; trastuzumab RP: 1 \[0.3%\]), and none experienced cardiac failure coincident with LVEF decline by ≥ 10% points and to \< 50% compared with baseline. Cardiac failure events were grade 1 or 2 and patients completed all planned doses of IP, indicating resolution or no worsening of the cardiac failure event.

During the adjuvant phase, 2 (0.6%), 1 (0.6%), and 1 (0.6%) patients in the ABP 980/ABP 980, trastuzumab RP/trastuzumab RP, and trastuzumab RP/ABP 980 groups, respectively, had at least one cardiac failure event. All cardiac failure events in the ABP 980/ABP 980 and trastuzumab RP/trastuzumab RP treatment groups were grade 1 or 2. One patient in the trastuzumab RP/ABP 980 arm (0.6%) had a cardiac failure event of grade 3 severity; all other cardiac failure events in this treatment group were grade 1 or 2. The grade 3 cardiac failure event was coincident with LVEF decline by ≥ 10% points and to \< 50% compared with baseline. This cardiac failure event occurred 371 days after study drug initiation, was considered related to the study drug, and the patient recovered/resolved with sequelae; the 79-year-old patient had no relevant cardiovascular medical history. One patient discontinued IP during the adjuvant phase because of cardiac failure.

Discussion {#Sec7}
==========

The results of the phase III LILAC study previously demonstrated that ABP 980 is similar to trastuzumab RP with respect to efficacy, safety, and immunogenicity in women with HER2-positive early breast cancer. Here, we extend these results by presenting the outcomes of a prespecified cardiac safety analysis of ABP 980 in that study. Although the mechanism is still not fully understood, cardiotoxicity is the most important limitation in the application of trastuzumab. Thus, cardiac safety is one of the most important parameters to carefully monitor when assessing the safety of a trastuzumab biosimilar.

Our results demonstrate a low incidence of cardiotoxicity following long-term (up to 1 year) treatment with the trastuzumab biosimilar ABP 980 in combination with chemotherapy. No correlation was observed between subjects with an LVEF decline of ≥ 10 percentage points and to \< 50% and subjects who experienced a cardiac failure EOI. There were no clinically meaningful differences in the incidence of LVEF decline between treatment arms in the adjuvant phase or over the entire study.

The limitation of the current analysis is that the study was not statistically powered to detect differences in cardiac parameters among the treatment groups, and that the small number of cardiovascular events noted during the study preclude more robust analyses.

Overall, the incidence of cardiac failure frequency in the LILAC study was within the expected range based on the label and published data for trastuzumab RP \[[@CR1], [@CR4]\]. Moreover, our analysis demonstrated comparable cardiac safety in patients who were switched from trastuzumab RP to ABP 980 following surgery compared with patients who were maintained on treatment with either ABP 980 or trastuzumab RP. This finding has important implications for clinicians who may consider switching patients from trastuzumab RP to ABP 980.

Conclusions {#Sec8}
===========

The results of this prespecified analysis of the LILAC study confirm the tolerability of ABP 980 and further demonstrate acceptable cardiac safety, which is a particular concern with trastuzumab therapy. No new or unexpected cardiac safety signals were observed with ABP 980 compared with trastuzumab RP, whether patients were started on ABP 980 or were switched from trastuzumab RP to ABP 980.
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